港股異動 | 復星醫藥高開6% 牽手真實生物聯合開發及獨家商業化阿茲夫定
格隆匯7月26日丨港股復星醫藥(2196.HK)高開6.38%,報33.35港元;A股復星醫藥(600196.SH)漲8.05%,報52.88元,總市值1355億元。復星醫藥公佈,2022年7月25日,公司控股子公司復星醫藥產業與真實生物簽訂《戰略合作協議》,雙方就推進聯合開發並由復星醫藥產業獨家商業化阿茲夫定等事宜達成戰略合作。此次合作領域包括將阿茲夫定用於新冠及艾滋病的預防及治療領域;擬合作區域為中國大陸以及中國大陸以外的全球地區,但不包括俄羅斯、烏克蘭、巴西及其他南美洲國家和地區。阿茲夫定片是我國自主研發的口服小分子新冠病毒肺炎治療藥物。昨日,國家藥監局應急附條件批准真實生物阿茲夫定片增加新冠肺炎治療適應症註冊申請,用於治療普通型新型冠狀病毒肺炎(COVID-19)成年患者。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.